EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection

Eric M Kofoed iD, Ignacio Aliagas, Terry Crawford, Jialin Mao, Seth F Harris, Min Xu, Shumei Wang, Ping Wu, Fang Ma, Kevin Clark, Jessica Sims, Yiming Xu und 22 weitere

mBio · 2024

DOI: 10.1128/mbio.00897-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, 2024. Verfasst von Eric M Kofoed und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Genentech Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Anti-Bacterial Agents, Acinetobacter Infections, IMP Dehydrogenase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guanine nucleotides are required for growth and viability of cells due to their structural role in DNA and RNA, and their regulatory roles in translation, signal transduction, and cell division. The natural antibiotic mycophenolic acid (MPA) targets the rate-limiting step in de novo guanine nucleotide biosynthesis executed by inosine-5´-monophosphate dehydrogenase (IMPDH). MPA is used clinically as an immunosuppressant, but whether in vivo inhibition of bacterial IMPDH (GuaB) is a valid antibacterial strategy is controversial. Here, we describe the discovery of extremely potent small molecule GuaB inhibitors (GuaBi) specific to pathogenic bacteria with a low frequency of on-target spontaneous resistance and bactericidal efficacy in vivo against Acinetobacter baumannii mouse models of infection. The spectrum of GuaBi activity includes multidrug-resistant pathogens that are a critical priority of new antibiotic development. Co-crystal structures of A. baumannii, Staphylococcus aureus , and Escherichia coli GuaB proteins bound to inhibitors show comparable binding modes of GuaBi across species and identifies key binding site residues that are predictive of whole-cell activity across both Gram-positive and Gram-negative clades of Bacteria. The clear in vivo efficacy of these small molecule GuaB inhibitors in a model of A. baumannii infection validates GuaB as an essential antibiotic target. IMPORTANCE The emergence of multidrug-resistant bacteria worldwide has renewed interest in discovering antibiotics with novel mechanism of action. For the first time ever, we demonstrate that pharmacological inhibition of de novo guanine biosynthesis is bactericidal in a mouse model of Acinetobacter baumannii infection. Structural analyses of novel inhibitors explain differences in biochemical and whole-cell activity across bacterial clades and underscore why this discovery may have broad translational impact on treatment of the most recalcitrant bacterial infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAnti-Bacterial AgentsAcinetobacter InfectionsIMP DehydrogenaseAnimalsMiceDisease Models, AnimalMicrobial Sensitivity TestsEnzyme InhibitorsBacterial ProteinsDrug DiscoveryStaphylococcus aureusEscherichia coliFemaleDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

Acinetobacter baumanniiantibiotic target validationbacterial geneticsmedicinal chemistrypharmacologystructural biology

Substanzen

Anti-Bacterial AgentsIMP DehydrogenaseEnzyme InhibitorsBacterial Proteins

Autor:innen und Institutionen

  • Department of Infectious Diseases, Genentech Inc., South San Francisco, California, USA.
  • Department of Discovery Chemistry, Genentech Inc., South San Francisco, California, USA.
  • Department of Medicinal Chemistry, Genentech Inc., South San Francisco, California, USA.
  • Department of Drug Metabolism and Pharmacokinetics, Genentech Inc., South San Francisco, California, USA.
  • Department of Structural Biology, Genentech Inc., South San Francisco, California, USA.
  • Department of Translational Immunology, Genentech Inc., South San Francisco, California, USA.

ORCID-Profile: Eric M Kofoed, Yutian Peng, Man Wah Tan

Förderung

  • NIGMS NIH HHS

Zitieren

APA

Kofoed, E. M., Aliagas, I., Crawford, T., Mao, J., Harris, S. F., Xu, M., Wang, S., Wu, P., Ma, F., Clark, K., Sims, J., Xu, Y., Peng, Y., Skippington, E., Yang, Y., Reeder, J., Ubhayakar, S., Baumgardner, M., Yan, Z., …, & Tan, M. W. (2024). Discovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection. mBio. https://doi.org/10.1128/mbio.00897-24

Vancouver

Kofoed EM, Aliagas I, Crawford T, Mao J, Harris SF, Xu M, et al. Discovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection. mBio. 2024. doi:10.1128/mbio.00897-24

BibTeX
@article{Kofoed2024,
  author = {Kofoed, Eric M and Aliagas, Ignacio and Crawford, Terry and Mao, Jialin and Harris, Seth F and Xu, Min and Wang, Shumei and Wu, Ping and Ma, Fang and Clark, Kevin and Sims, Jessica and Xu, Yiming and Peng, Yutian and Skippington, Elizabeth and Yang, Ying and Reeder, Janina and Ubhayakar, Savita and Baumgardner, Matt and Yan, Zhengyin and Chen, Jacob and Park, Summer and Zhang, Hua and Yen, Chun-Wan and Lorenzo, Maria and Skelton, Nicholas and Liang, Xiaorong and Chen, Liuxi and Hoag, Bridget and Li, Chun Sing and Liu, Zhiguo and Wai, John and Liu, Xingrong and Liang, Jun and Tan, Man Wah},
  title = {Discovery of GuaB inhibitors with efficacy against Acinetobacter baumannii infection},
  journal = {mBio},
  year = {2024},
  doi = {10.1128/mbio.00897-24}
}
Kostenlos starten →